Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a gene encoding the K-Ras protein, a small GTPase that plays a central role in cell signaling pathways regulating proliferation, differentiation, and survival. KRAS mutations, particularly at codons 12, 13, and 61, lock KRAS in its active (GTP-bound) state, leading to continuous activation of proliferative and survival signaling pathways independent of external stimuli, driving uncontrolled cell division and tumorigenesis. Specific inhibitors have been developed targeting the KRAS(G12C) mutant.
Direct covalent inhibition of KRAS(G12C); inhibition of upstream activators (EGFR); inhibition of downstream effectors (RAF/MEK/ERK, PI3K/mTOR)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kirsten rat sarcoma viral oncogene homolog (Mutant) (KRAS (Mutant)).